Trial Profile

A Phase 3 Study to Evaluate Weight Gain of ALKS 3831 Compared to Olanzapine in Adults With Schizophrenia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Olanzapine/samidorphan (Primary) ; Olanzapine
Indications Schizophrenia
Focus Registrational; Therapeutic Use
Acronyms ENLIGHTEN-2
Sponsors Alkermes; Alkermes plc

Most Recent Events

21 May 2026 According to Alkermes plc media release, data from the trial were presented at the Psych Congress NP Institute (NPI), March 19-22, Nashville, Tenn.
03 Jan 2024 According to Alkermes plc media release, topline result is announced
11 Sep 2023 According to a Alkermes media release, results of meta-analysis using individual subject-level data from this trial presented at the 36th Annual Psych Congress (Psych Congress), which took place Sept. 6-10, 2023 in Nashville.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com